Scottish Seminar Series - come and find out about our open calls for proposals

on .

Thursday 8th December 2016 - 13.00 to 14.00
University of Glasgow - Wolfson Medical School
Gannochy Lecture Theatre, Room 248 Wolfson Medical School Building,University Place, Gilmorehill Campus, Glasgow G12 8QQ

Thursday 8th December 2016 - 15.00 to 16.00
University of Glasgow - Wolfson Wohl Cancer Research Centre
Seminar Room, Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Bearsden, G61 1QH

Friday 9th December 2016 - 12.00 to 13.00
University of Aberdeen - Level 5 conference room - Institute for Medical Sciences (IMS), Forrester Hill Campus, Aberdeen AB25 2ZD

We are looking for biologists and clinicians with phenotypic assays or assay-concepts, that are interested in translating their research. We offer the opportunity to get these assays screened to industry standards against best-in-class small molecule compound libraries. In this seminar we will present the opportunities for assay development and phenotypic screening that are available at NPSC.

NPSC is a world-class facility for phenotypic screening run by an interdisciplinary team of scientists and engineers who collaborate to advance the use of complex biology and to drive innovation. NPSC was set up to complement the activities of the target-based screening centres, taking a more holistic approach to understanding disease at the cellular and tissue level. Focused on using “high-content” image-based approaches to hit discovery, initial emphasis will be on tackling complex, multi-faceted diseases, employing the most physiologically relevant assays possible.
Screens are performed using high quality compound collections to generate either new understanding of disease pathology and toolbox reagents for further academic use, or validated chemical start points for pre-clinical drug development. Phenotypic assay development will take place as a joint effort between the NPSC and the academic lab or clinician, thereby bridging the gap between early stage data and an industry-standard assay.

In addition to being accessible via existing funding routes, the NPSC has established the Phenomics Discovery Initiative (PDi), a public-private partnership between industrial pharmaceutical companies and NPSC. PDi seeks to identify, develop, screen and validate innovative phenotypic assays that are relevant to human disease. PDi phenotypic assays are recruited from proposals made by academics, clinicians and SMEs. Selected proposals are screened free of charge.

Phenotypic screening embraces the complexity of organisms, tissues and cells in order to identify bioactive agents such as small molecules and antibodies. Rather than being focused on biochemical assays on an isolated target molecule, it relies on a more holistic and empirical approach often using live cell assay systems. When integrated early in the drug discovery process, phenotypic screening hits can progress faster as they already act in the correct context, improving success rates for lead selection/optimization, and reducing failure in phase II and III due to poor safety and low efficacy.


NPSC is a facility run and operated by the Universities of Dundee, Edinburgh and Oxford, which are registered UK-based charities. 

Copyright © 2016.